SPTLC1P1

Across TCGA pan-cancer cohorts, SPTLC1P1 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of SPTLC1P1’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where SPTLC1P1 RNA is repressed in tumor relative to normal tissue. In most cancer types SPTLC1P1 is over-expressed in tumor, although a few such as PAAD and BRCA show the opposite, repressed pattern.

PAAD, LUAD, and COAD are the cancer types where SPTLC1P1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SPTLC1P1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PAAD	Female	All	−0.710	.044	2	view →
LUAD	Male	All	+0.491	.037	2	view →
COAD	All	III,IV	+0.270	.011	2	view →
BRCA	All	III,IV	−0.235	.033	2	view →
THCA	All	All	−0.165	<.001	2	view →
LIHC	Female	II,III,IV	+0.076	.032	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

SPTLC1P1–PAAD

Open the PAAD breakdown →